-
EP3816166
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3816166
| EP3816166 - TLR7 AGONIST AND PHARMACEUTICAL COMBINATION THEREOF FOR TREATING LUNG CANCER [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 09.05.2024 Database last updated on 19.07.2024 | |
| Former | Request for examination was made Status updated on 03.04.2021 | ||
| Former | The international publication has been made Status updated on 30.11.2019 | Most recent event Tooltip | 10.05.2024 | First examination report | Applicant(s) | For all designated states Chia Tai Tianqing Pharmaceutical Group Co., Ltd. No. 369 Yuzhou South Road Lianyungang, Jiangsu 222062 / CN | [2021/18] | Inventor(s) | 01 /
ZHANG, Xiquan No.369 Yuzhou South Rd. Lianyungang, Jiangsu 222062 / CN | 02 /
YANG, Ling No.369 Yuzhou South Rd. Lianyungang, Jiangsu 222062 / CN | 03 /
ZHANG, Ying No.369 Yuzhou South Rd. Lianyungang, Jiangsu 222062 / CN | 04 /
ZHANG, Mincheng No.369 Yuzhou South Rd. Lianyungang, Jiangsu 222062 / CN | 05 /
SONG, Wei No.369 Yuzhou South Rd. Lianyungang, Jiangsu 222062 / CN | 06 /
XU, Hongjiang No.369 Yuzhou South Rd. Lianyungang, Jiangsu 222062 / CN | [2021/18] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [2021/18] | Application number, filing date | 19807809.9 | 24.05.2019 | [2021/18] | WO2019CN88360 | Priority number, date | CN201810560770 | 25.05.2018 Original published format: CN201810560770 | [2021/18] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2019223788 | Date: | 28.11.2019 | Language: | ZH | [2019/48] | Type: | A1 Application with search report | No.: | EP3816166 | Date: | 05.05.2021 | Language: | EN | [2021/18] | Search report(s) | International search report - published on: | CN | 28.11.2019 | (Supplementary) European search report - dispatched on: | EP | 04.03.2022 | Classification | IPC: | A61K31/519, A61K31/5377, A61K31/551, A61P35/00 | [2022/14] | CPC: |
A61K31/519 (EP,KR,US);
A61K31/4709 (EP,KR);
A61K31/5377 (EP,KR);
A61K31/551 (EP,KR);
A61K45/06 (KR);
A61P35/00 (EP,KR,US);
| C-Set: |
A61K31/4709, A61K2300/00 (EP);
A61K31/519, A61K2300/00 (EP) |
| Former IPC [2021/18] | C07D487/04, C07D519/00, A61K31/519, A61K31/5377, A61K31/551, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/18] | Title | German: | TLR7-AGONIST UND PHARMAZEUTISCHE KOMBINATION DAVON ZUR BEHANDLUNG VON LUNGENKREBS | [2021/18] | English: | TLR7 AGONIST AND PHARMACEUTICAL COMBINATION THEREOF FOR TREATING LUNG CANCER | [2021/18] | French: | AGONISTE DU TLR7 ET COMBINAISON PHARMACEUTIQUE DE CELUI-CI POUR LE TRAITEMENT DU CANCER DU POUMON | [2021/18] | Entry into regional phase | 01.12.2020 | Translation filed | 01.12.2020 | National basic fee paid | 01.12.2020 | Search fee paid | 01.12.2020 | Designation fee(s) paid | 01.12.2020 | Examination fee paid | Examination procedure | 01.12.2020 | Examination requested [2021/18] | 03.10.2022 | Amendment by applicant (claims and/or description) | 08.05.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 01.12.2020 | Renewal fee patent year 03 | 21.03.2022 | Renewal fee patent year 04 | 14.03.2023 | Renewal fee patent year 05 | 18.03.2024 | Renewal fee patent year 06 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2011031965 (GILEAD SCIENCES INC [US], et al); | [Y]EP3190113 (CHAI TAI TIANQING PHARMACEUTICAL GROUP CO LTD [CN]); | International search | [X]CN105367576 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [A]CN105367576 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [A]WO2016107536 (MEDSHINE DISCOVERY INC [CN]); | [X]CN107043377 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [A]CN107043377 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [X]CN107043379 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [A]CN107043379 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [X]CN107043380 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD); | [A]CN107043380 (CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD) | by applicant | WO2016023511 | WO2017076346 |